Jiangsu Chuangjian Medical Technology Co., Ltd. *** hereinafter referred to as "Chuangjian Medical") has officially launched the A-share IPO process.
Founded in 2015, Neo-Health Medical is a scientific and technological innovation enterprise focusing on the R&D, production and sales of new biomaterials and innovative protein nucleic acid drugs. At present, Neo-Health has successively completed the large-scale and standardized production of recombinant collagen I, II, III, and XVII, filling the "ton-level" production capacity gap in the field of global recombinant collagen materials for more than 30 years.
Among them, recombinant XVII type is the first transmembrane collagen that Neo-Health has successfully independently developed and achieved large-scale production in the world, which can be applied to the field of beauty and personal care.
At present, Neo-Health Medical mainly has three business segments: biological raw materials, medical cosmetics terminals, and ODM.
In recent years, Neo-Health has received two consecutive rounds of financing with a cumulative scale of over 400 million yuan. In July 2022, Neo-Health received Series A financing led by Shiseido Ziyue** and followed by Huafang Capital, CDH Baifu and Holley Pharmaceutical. It is worth mentioning that this is the first investment of Ziyue** in China. In September 2023, Neo-Health received Series B financing co-led by L Catterton and CLSA Capital, followed by Venture Capital and Mingfeng Capital, which was formed in 2016 by the merger of two private equity firms, L Capital and Catterton, a private equity firm owned by LVMH.
According to Frost & Sullivan**, by 2026, the market share of collagen-based professional care products will surpass hyaluronic acid, with a compound annual growth rate of 526%；By 2027, the overall market size of collagen in China will reach 173.8 billion yuan, of which the market size of recombinant collagen products will be 108.3 billion yuan, accounting for 623%。